Complete remission is the greatest predictor of long-term survival.
ONCOLOGY
Fully funded by 
Content independently selected
-
Follicular lymphoma: 13-year data for rituximab-based frontline therapy -
Hodgkin lymphoma: aprepitant reduces vomiting in pediatric patients No significant reduction in incidence of nausea.
-
MCL: consolidation radioimmunotherapy extends survival in unfit patients Almost 6 years median PFS in patients with complete response to frontline induction.
-
Findings from the REMoDL-B trial published in the Lancet Oncology.
-
DLBCL: dose-adjusted EPOCH-R more toxic than R-CHOP Phase 3 study fails to show progression-free or overall survival benefit.
-
Last week, French authorities announced a restriction on macrotextured and polyurethane-coated breast implants.
-
Aggressive lymphoma: cachexia shows sex-specific prognostic utility Data show correlation with changes in metabolism, immune function.
-
Primary extranodal cHL: more intensive therapy may be needed Data show short remission, high relapse rates, and inferior survival.
-
NHL: polatuzumab vedotin + rituximab favored in final analysis ROMULUS data show longer duration of action in relapsed/refractory disease.
-
AACR 2019—Umbralisib delivers 52% response rate in marginal zone lymphoma Data from the ongoing phase 2b UNITY-NHL trial.
-
Marginal zone lymphoma: long-term data for lenalidomide-rituximab Regimen switches chemotherapy for lenalidomide without compromise.
-
DLBCL: phase 3 results for frontline ibrutinib plus R-CHOP Numerical improvement in survival among younger patients.
-
Indolent NHL: lenalidomide-rituximab ups PFS in phase 3 trial 54% reduction in risk of progression or death vs rituximab alone.
-
NICE approves tisagenlecleucel for B-cell lymphoma The treatment is to be made available under the Cancer Drugs Fund